Patient Power Community member, Francis, asks “Can refractory, high-risk myeloma patients become refractory to daratumumab?” Dr. Jatin Shah from the University of Texas MD Anderson Cancer Center responds to this question and goes on to discuss promising treatment options in clinical trials, specifically related to immunotherapy and checkpoint inhibitors.
Can High-Risk Myeloma Patients Become... - Myeloma America S...
Can High-Risk Myeloma Patients Become Refractory to Certain Monoclonal Antibodies?
Written by
mcints
To view profiles and participate in discussions please or .
Read more about...
Not what you're looking for?
You may also like...
multiple myeloma on pancreatic and pelvic as extramedullary plasmacytoma
these patients are able to finish the treatment in full recovery.
Is it true to multiple myeloma...
